Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADGINYSE:AIMNYSE:IKTNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADGIAdagio Therapeutics$4.21$2.41▼$78.82$504.98MN/A2.27 million shs22,357 shsAIMAIM ImmunoTech$9.21+11.0%$9.13$0.06▼$14.93$7.04M0.94571,052 shs87,143 shsIKTInhibikase Therapeutics$1.66-2.4%$1.99$1.12▼$4.20$123.41M0.94242,650 shs278,054 shsPRMEPrime Medicine$2.07+15.0%$1.45$1.11▼$6.75$271.78M1.551.43 million shs5.92 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADGIAdagio Therapeutics0.00%0.00%0.00%0.00%0.00%AIMAIM ImmunoTech0.00%+0.77%+0.77%-34.40%-77.56%IKTInhibikase Therapeutics0.00%-10.75%-6.21%-29.96%+18.57%PRMEPrime Medicine0.00%+41.78%+60.47%+1.97%-65.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADGIAdagio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAIMAIM ImmunoTech1.8315 of 5 stars3.50.00.00.02.21.70.0IKTInhibikase Therapeutics1.4768 of 5 stars3.31.00.00.00.00.01.3PRMEPrime Medicine3.8304 of 5 stars4.41.00.00.03.35.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADGIAdagio Therapeutics 0.00N/AN/AN/AAIMAIM ImmunoTech 3.00Buy$275.002,885.88% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50291.57% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08387.12% UpsideCurrent Analyst Ratings BreakdownLatest ADGI, AIM, PRME, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADGIAdagio TherapeuticsN/AN/AN/AN/A$5.02 per shareN/AAIMAIM ImmunoTech$146K48.19N/AN/A$0.20 per share46.05IKTInhibikase Therapeutics$260K474.65N/AN/A$1.78 per share0.93PRMEPrime Medicine$3.85M70.67N/AN/A$1.37 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADGIAdagio Therapeutics-$226.79M-$3.15N/AN/AN/AN/A-57.14%-50.28%N/AAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADGIAdagio TherapeuticsN/AN/AN/AN/AN/AAIMAIM ImmunoTechN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4569.86%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADGIAdagio TherapeuticsN/A7.097.09AIMAIM ImmunoTech0.050.750.75IKTInhibikase TherapeuticsN/A0.850.85PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADGIAdagio Therapeutics96.94%AIMAIM ImmunoTech12.02%IKTInhibikase Therapeutics3.81%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipADGIAdagio TherapeuticsN/AAIMAIM ImmunoTech0.02%IKTInhibikase Therapeutics7.30%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADGIAdagio Therapeutics2,021108.83 millionN/ANot OptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableADGI, AIM, PRME, and IKT HeadlinesRecent News About These CompaniesHead to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)June 20 at 3:27 AM | americanbankingnews.comPrime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment OpportunityJune 17, 2025 | tipranks.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in StockJune 17, 2025 | insidertrades.comInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of StockJune 16, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in StockJune 12, 2025 | marketbeat.comTwo Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)June 10, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)May 30, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comPrime Medicine's (PRME) "Neutral" Rating Reaffirmed at CitigroupMay 28, 2025 | marketbeat.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.comChardan Capital Raises Earnings Estimates for Prime MedicineMay 25, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Prime MedicineMay 24, 2025 | marketbeat.comWedbush Has Bullish Estimate for Prime Medicine Q3 EarningsMay 23, 2025 | marketbeat.comWestwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)May 23, 2025 | marketbeat.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21, 2025 | nasdaq.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20, 2025 | thepharmaletter.comPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20, 2025 | fiercebiotech.comPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20, 2025 | biopharmadive.comCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20, 2025 | bostonglobe.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAlphabet Enters a Bull Market: Is It Time to Buy?By Ryan Hasson | June 14, 2025View Alphabet Enters a Bull Market: Is It Time to Buy?Target's Big Bet: Is It a Cheap Stock or a Value Trap? By Jeffrey Neal Johnson | May 29, 2025View Target's Big Bet: Is It a Cheap Stock or a Value Trap? Will Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?MongoDB Affirms Outlook and Accelerates Stock Price ReversalBy Thomas Hughes | June 6, 2025View MongoDB Affirms Outlook and Accelerates Stock Price ReversalADGI, AIM, PRME, and IKT Company DescriptionsAdagio Therapeutics NASDAQ:ADGIAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.AIM ImmunoTech NYSE:AIM$9.21 +0.91 (+10.96%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.69 +0.48 (+5.22%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Inhibikase Therapeutics NYSE:IKT$1.66 -0.04 (-2.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 06/20/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Prime Medicine NYSE:PRME$2.07 +0.27 (+15.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.08 +0.02 (+0.72%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
